Ressources and Downloads

WP1 - Excellence in ERIC operations and management

WP2 - Academic Compound Acquisition

WP3 - TA – Demonstration of EU-OPENSCREEN’s integrated Screening and Medicinal Chemistry capacities

WP4 - Extension of capacities 1: Fragment-based screening

WP5 - Extension of capacities 2: Chemical Proteomics Services

WP6 - Improving data utilisation and impact for Users

WP7 - Industry Engagement

WP8 - Training

WP9 - Project Management, Outreach and Communication

WP10 - Ethics

D1.1 Report on improvements to the access and workflows (Month 12)

D1.2 Handbook and defined user workflows for two new categories of partner sites (Month 46)

D1.3 Report on engagement measures and successes for extension of EU-OS membership (Month 46)

D1.4 Socio-economic impact study and documented refined KPIs (Month 40)

D1.5 Enhanced Business Plan and financial sustainability model based on EU-OS-DRIVE outcomes (Month 40)

D2.1 Improved protocols for compound sourcing and acquisition based on EU-OS Ambassador feedback, including a directory of cooperating chemists from each country (Month 12)

D2.2 Report on the evaluation of tools to improve compound registration (Month 18)

D2.3 Final report on the EU-OS academic compound library (Month 47)

D3.1 Report on outcomes of the Screening projects (Month 26)

D3.2 Report on outcomes of the Chemical Optimisation projects (Month 46)

D4.1 FBDD chemical evolution consultation service guidelines (Month 12)

D4.2 Publication describing the performance of the fragment library in screening campaigns (Month 40)

D5.1 Mode of action or compound distribution report for compounds from selected projects from phase 1 (responsibility of sites providing access) (Month 24)

D5.2 Mode of action or compound distribution report for compounds from selected projects from phase 2 (responsibility of sites providing access) (Month 48)

D6.1 Report on existing data transfer procedures and gap analysis (Month 6)

D6.2 Report on implementation of enhanced transfer procedures for data from EU-OS partner sites (Month 46)

D6.3 Report on the translation module for EU-OS screening centers (Month 46)

D6.4 Recommendations for data reproducibility training (Month 36)

D6.5 Data Management Plan (Month 6)

D7.1 Roadmap for industry interactions and establishment of industry involvement in EU-OPENSCREEN's activities (Month 8)

D7.2 Report on the status of co-developed screening technologies (Month 47)

D7.3 Innovation management plan (Month 47)

D8.1 Report on available courses relevant for users and staff of EU-OS (Month 12)

D8.2 Report on newly developed courses organized by EU-OS-DRIVE (Month 18)

D8.3 Report on co-ordination of joined training with other BMS ESFRI projects and establishing new collaborative links (Month 18)

D9.1 Management Guidelines (Month 2 delayed to M20)

D9.2 Gender Action Plan (Month 12)

D9.3 Report on scientific publications and dissemination / outreach activities to new communities (Month 47)

D9.4 Report on sustainability aspects and future perspectives for forming major strategic cooperations in the fields of chemical biology and academic drug discovery. Audiences are policy makers and funding bodies (Month 48)

All deliverables related to Ethics are confidential:

D10.1 HCT – Requirement No. 1

D10.2 A - Requirement No. 2

D10.3 NEC - Requirement No. 3

Please contact drive@eu-openscreen.eu for further information.

High-throughput screening quality control general guidelines

• Nature Reviews Drug Discovery advertisement one-pager on EU-OPENSCREEN-DRIVE open calls from July 2019
• Nature email advertisement on EU-OPENSCREEN-DRIVE open calls from September 2019